KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Emergent BioSolutions (EBS) Income from Continuing Operations (2016 - 2025)

Emergent BioSolutions (EBS) has 15 years of Income from Continuing Operations data on record, last reported at 54600000.0 in Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 74.44% year-over-year to 54600000.0; the TTM value through Dec 2025 reached 52600000.0, up 127.6%, while the annual FY2025 figure was 52600000.0, 127.6% up from the prior year.
  • Income from Continuing Operations reached 54600000.0 in Q4 2025 per EBS's latest filing, down from 51200000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 177900000.0 in Q4 2021 and bottomed at 283100000.0 in Q2 2024.
  • Average Income from Continuing Operations over 5 years is 45100000.0, with a median of 32000000.0 recorded in 2021.
  • Peak YoY movement for Income from Continuing Operations: surged 657.6% in 2021, then tumbled 4932.43% in 2023.
  • A 5-year view of Income from Continuing Operations shows it stood at 177900000.0 in 2021, then crashed by 142.61% to 75800000.0 in 2022, then soared by 34.7% to 49500000.0 in 2023, then surged by 36.77% to 31300000.0 in 2024, then plummeted by 74.44% to 54600000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 54600000.0 in Q4 2025, 51200000.0 in Q3 2025, and 12000000.0 in Q2 2025.